Who makes Azithromycin neubilization?

Azithromycin neubilization is developed by Alexandria University.

What development phase is Azithromycin neubilization in?

Azithromycin neubilization is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Azithromycin neubilization

Alexandria University · FDA-approved active Small molecule Quality 2/100

Azithromycin neubilization, developed by Alexandria University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique nebulization formulation, which differentiates it from oral and intravenous administration options. The primary risk is the lack of significant revenue data, which may impact its market competitiveness and investment attractiveness.

At a glance

Generic name	Azithromycin neubilization
Sponsor	Alexandria University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

THE EFFECT OF NEBULIZED AZITHROMYCIN AS THERAPY FOR BRONCHOPULMONARY DYSPLASIA (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Azithromycin neubilization CI brief — competitive landscape report
Azithromycin neubilization updates RSS · CI watch RSS
Alexandria University portfolio CI